BofA still bullish on Bio-Reference Labs despite Q4 outlook

|About: Bio-Reference Laboratories,... (BRLI)|By:, SA News Editor

BofA is out with a cautiously bullish note on Bio-Reference Labs (BRLI -2.1%) on the heels of the company's pre-announcement late last month.

"While we are maintaining our Buy rating ... we are now modelling a weaker H1 2014 EPS outlook on lower near term profit forecasts and relying on a stronger H2 2014 experience," analyst Robert Willoughby says, lowering his price target by a dollar to $33.

From last month: BRLI slumps after guidance update